Breakthrough Cancer Immunotherapy Shows 50% Response Rate in Advanced Sarcomas
For patients with advanced soft tissue sarcomas, the statistics have been grim: second-line treatments typically show less than 5% response rates, and median survival often measures in months. But Iovance Biotherapeutics has announced results that could rewrite these outcomes, with